There were two HUGE movers in biotech today, and the equities markets in general were up as well after a rough start. One of these was CUR, Neuralstem Inc, which was up over +30% for the session, after reporting positive results on a pre-clinical trial of it’s NSI-189 nervous system therapy. Meanwhile, the biggest mover was RETA, Reata Pharmaceuticals, which reported positive phase 2 data for Bardoxolone Methyl, which it is developing to treat kidney ailments. RETA was up over +58% on the news, and the stock has more than doubled in price since early April 2018. Here’s a quick overview of what happened.